FDA Drug Approvals
Darzalex Faspro (daratumumab and hyaluronidase-fihj): Label expansion approved 27-Jan-2026 in combination with VRd for newly diagnosed multiple myeloma patients ineligible for transplant. Johnson & Johnson. FDA Link
Zycubo (copper histidinate): Approved 12-Jan-2026 as the first treatment for Menkes disease, a rare copper metabolism disorder. FDA Link
Fibryga (fibrinogen, human): Expanded 2-gram kit approved 07-Jan-2026 for acquired fibrinogen deficiency, designed for faster administration in critical bleeding. Octapharma. FDA Link
Cablivi (caplacizumab-yhdp): Pediatric expansion approved 05-Jan-2026 for children 12 years with acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi. FDA Link
Generic Glatiramer Acetate: Approved 05-Jan-2026 as the first complex injectable generic for relapsing multiple sclerosis. ScinoPharm. FDA Link
ProlivRx: Approved Jan 2026 as the first at-home, physician-directed neuromodulation device for Major Depressive Disorder (MDD).
M&A Deals
GSK acquires RAPT Therapeutics: $2.2 billion (Announced Jan 20, 2026). Secures RAPT’s oral small molecules for inflammation and oncology, strengthening GSK's respiratory/immunology pipeline. Source
AbbVie & RemeGen Licensing: $5.6 billion total (Jan 12, 2026). AbbVie gains rights to a bispecific antibody for oncology, continuing its aggressive expansion in targeted therapies. Source
Lilly & Seamless Therapeutics: $1.12 billion (Jan 28, 2026). A strategic collaboration focused on modular gene editing for neurological disorders. Source
AstraZeneca & SanegeneBio: $1.7 billion (Jan 30, 2026). Licensing deal for an RNAi technology platform to address metabolic and cardiovascular indications. Source
BMS & Janux Therapeutics: $1.035 billion (Jan 2026). Licensing deal for tumor-activated bispecific antibodies targeting solid tumors. Source
Clinical Trial Setbacks
Bausch Health (rifaximin SSD): Phase 3 Red-C trials failed (Jan 23, 2026). The Xifaxan successor did not meet primary objectives for the prevention of hepatic encephalopathy in cirrhosis patients. Source
Milvexian (J&J/BMS): Phase 3 futility analysis (Feb 2026) led to the early termination of the ACS (Acute Coronary Syndrome) study, though other Phase 3 indications remain active. Source
Technological Breakthroughs
NIH "Digital Twin" of the Eye: In Feb 2026, the NIH unveiled a high-resolution 3D digital replica of retinal pigment epithelial cells, providing a new AI-driven modeling platform to accelerate AMD drug discovery. Source
AI-Driven IND Streamlining: Data from Parexel in early 2026 shows AI systems are now preparing IND (Investigational New Drug) submissions 50% faster, significantly cutting the time from "ready" to "regulatory review." Source
Market Insights
The "Obesity Platform" Era: Experts at the 2026 J.P. Morgan Healthcare Conference noted a shift from mere GLP-1 novelty to supply chain scale and multi-modal platforms (oral, weekly, and combination therapies) to capture the projected $200B market. Source
Patent Cliff Pressure: 2026 marks the beginning of the "cliff," with over 40% of Big Pharma revenue at risk of loss of exclusivity (LoE) by 2030, driving the current 15% surge in late-stage M&A. Source
Summary Table: Recent Major FDA Actions
Brand Name | Active Ingredient | Company | Indication | Approval Date |
Darzalex Faspro | Daratumumab | J&J | Newly Diagnosed Multiple Myeloma | 27-Jan-2026 |
Zycubo | Copper histidinate | N/A | Menkes Disease | 12-Jan-2026 |
Fibryga (2g) | Fibrinogen | Octapharma | Acquired Fibrinogen Deficiency | 07-Jan-2026 |
Cablivi | Caplacizumab | Sanofi | Pediatric aTTP | 05-Jan-2026 |
N/A (Generic) | Glatiramer Acetate | ScinoPharm | Relapsing Multiple Sclerosis | 05-Jan-2026 |
ProlivRx | Neuromodulation | ProlivRx | MDD (At-Home Device) | Jan-2026 |
Quick Links
Clinical Trials Dashboard: https://lebolger.github.io/Intellitrials/2026dashboard.html
M&A Tracker: https://lebolger.github.io/Intellitrials/docs/mnatracker.html
FDA Approvals: https://lebolger.github.io/Intellitrials/fda-approvals.html
